Henneke G, Koundrioukoff S, Hübscher U (July 2003). "Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation". Oncogene. 22 (28): 4301–4313. doi:10.1038/sj.onc.1206606. PMID12853968. S2CID5787920.
Ohtoshi A, Maeda T, Higashi H, Ashizawa S, Yamada M, Hatakeyama M (January 2000). "beta3-endonexin as a novel inhibitor of cyclin A-associated kinase". Biochem. Biophys. Res. Commun. 267 (3): 947–952. doi:10.1006/bbrc.1999.2007. PMID10673397.
Joaquin M, Bessa M, Saville MK, Watson RJ (November 2002). "B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107". Oncogene. 21 (52): 7923–7932. doi:10.1038/sj.onc.1206001. PMID12439743. S2CID21761703.
Marti A, Wirbelauer C, Scheffner M, Krek W (May 1999). "Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation". Nat. Cell Biol. 1 (1): 14–19. doi:10.1038/8984. PMID10559858. S2CID8884226.
Bukholm IR, Bukholm G, Nesland JM (Jul 2001). "Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas". Int. J. Cancer. 93 (2): 283–287. doi:10.1002/ijc.1311. PMID11410878. S2CID10543682.
Henneke G, Koundrioukoff S, Hübscher U (July 2003). "Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation". Oncogene. 22 (28): 4301–4313. doi:10.1038/sj.onc.1206606. PMID12853968. S2CID5787920.
Ohtoshi A, Maeda T, Higashi H, Ashizawa S, Yamada M, Hatakeyama M (January 2000). "beta3-endonexin as a novel inhibitor of cyclin A-associated kinase". Biochem. Biophys. Res. Commun. 267 (3): 947–952. doi:10.1006/bbrc.1999.2007. PMID10673397.
Joaquin M, Bessa M, Saville MK, Watson RJ (November 2002). "B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107". Oncogene. 21 (52): 7923–7932. doi:10.1038/sj.onc.1206001. PMID12439743. S2CID21761703.
Marti A, Wirbelauer C, Scheffner M, Krek W (May 1999). "Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation". Nat. Cell Biol. 1 (1): 14–19. doi:10.1038/8984. PMID10559858. S2CID8884226.
Bukholm IR, Bukholm G, Nesland JM (Jul 2001). "Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas". Int. J. Cancer. 93 (2): 283–287. doi:10.1002/ijc.1311. PMID11410878. S2CID10543682.
Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N, Namba M (Jan–Feb 2001). "Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas". Anticancer Res. 21 (1B): 657–662. PMID11299822.
Henneke G, Koundrioukoff S, Hübscher U (July 2003). "Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation". Oncogene. 22 (28): 4301–4313. doi:10.1038/sj.onc.1206606. PMID12853968. S2CID5787920.
Joaquin M, Bessa M, Saville MK, Watson RJ (November 2002). "B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107". Oncogene. 21 (52): 7923–7932. doi:10.1038/sj.onc.1206001. PMID12439743. S2CID21761703.
Marti A, Wirbelauer C, Scheffner M, Krek W (May 1999). "Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation". Nat. Cell Biol. 1 (1): 14–19. doi:10.1038/8984. PMID10559858. S2CID8884226.
Shapiro SD, Ranjan AK, Kawase Y, Cheng RK, Kara RJ, Bhattacharya R, Guzman-Martinez G, Sanz J, Garcia MJ, Chaudhry HW (2014). "Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes". Sci Transl Med. 6 (224): 224ra27. doi:10.1126/scitranslmed.3007668. PMID24553388. S2CID20386712.
Bukholm IR, Bukholm G, Nesland JM (Jul 2001). "Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas". Int. J. Cancer. 93 (2): 283–287. doi:10.1002/ijc.1311. PMID11410878. S2CID10543682.